- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 09.07. | Roth/MKM initiates OS Therapies stock with buy on therapy outlook | 2 | Investing.com | ||
| 08.07. | OS Therapies: OS Therapies Accepts New FDA Meeting Request to Review Biomarker Data as Part of BEST Program | 379 | Newsfile | New York, New York and Rockville, Maryland--(Newsfile Corp. - July 8, 2026) - OS Therapies, Inc. (NYSE American: OSTX) ("OS Therapies" or "the Company"), the world leader in gene-edited, Listeria-based... ► Artikel lesen | |
| 06.07. | OS Therapies: OS Therapies Third Quarter 2026 Corporate Outlook | 730 | Newsfile | New York, New York and Rockville, Maryland--(Newsfile Corp. - July 6, 2026) - OS Therapies, Inc. (NYSE American: OSTX) ("OS Therapies" or "the Company"), the world leader in gene-edited, Listeria-based... ► Artikel lesen | |
| 02.07. | OS Therapies Inc - 8-K, Current Report | 1 | SEC Filings | ||
| 02.07. | OS Therapies: OS Therapies Appoints Dr. Craig Eagle to Board of Directors | 919 | Newsfile | Company secures $10 million line of credit supported by OS Therapies UK tax creditsNew York, New York and Rockville, Maryland--(Newsfile Corp. - July 2, 2026) - OS Therapies, Inc. (NYSE American:... ► Artikel lesen | |
| 30.06. | OS Therapies: OS Therapies Provides U.S. Regulatory Update | 692 | Newsfile | Type B Meeting requested to follow up on September 2025 End of Phase 2 FDA Meeting guidance on statistical methods to be used for BLA SubmissionSeeking to align FDA with MHRA & EMA on 3-year overall... ► Artikel lesen | |
| OS THERAPIES Aktie jetzt für 0€ handeln | |||||
| 26.06. | OS Therapies: OS Animal Health Announces Peer-Reviewed Publication of Clinical Trial Data for OST-HER2 Plus Palliative Radiation as Frontline Treatment in Canine Osteosarcoma | 585 | Newsfile | 20% of OST-HER2 treated dogs survived 2-year vs. 1% in control group (p = 0.00995)Over 15,000 dogs per year diagnosed with osteosarcomaCompany expects to submit U.S. Department of Agriculture meeting... ► Artikel lesen | |
| 08.06. | OS Therapies: OS Therapies Achieves Global Regulatory Alignment on Design of Phase 3 Trial of OST-HER2 in Fully Resected, Pulmonary Metastatic Osteosarcoma | 368 | Newsfile | Confirmatory Phase 3 trial to commence prior to BLA grant under Accelerated Approval Program in the U.S. and Conditional MAA in the U.K., Europe and AustraliaPatent pending pharmacodynamic response... ► Artikel lesen | |
| 02.06. | OS Therapies Says New Bone Cancer Data Strengthens Case For Regulatory Filings | 2 | Benzinga.com | ||
| 02.06. | OS Therapies: OS Therapies Achieves Statistically Significant 2.5-Year Overall Survival in Phase 2b Trial of OST-HER2 in Fully Resected Pulmonary Metastatic Osteosarcoma | 803 | Newsfile | 75% 2.5-year overall survival for OST-HER2 vs. 47% pooled historical control (p = 0.003), with no new patient deaths reported since the 2-year overall survival data (75% vs. 60%, p = 0.034)Updated... ► Artikel lesen | |
| 29.05. | OS Therapies: OS Therapies Announces the Publication of Four Articles on OST-HER2 and Osteosarcoma in Drug Discovery World | 556 | Newsfile | The Company confirms that it will release 2.5 year overall survival data from Phase 2b clinical trial OST-HER2 in the prevention or delay of recurrence in fully-resected pulmonary metastatic osteosarcoma... ► Artikel lesen | |
| 26.05. | OS Therapies: OS Therapies to Attend Upcoming Medical, Financial and Industry Conferences | 528 | Newsfile | ASCO 2026: 2.5-Year Overall Survival DataJefferies Healthcare Conference: Partnering & Investor meetingsBIO International Convention: Panel ParticipationMIB Agents Factor Osteosarcoma Conference:... ► Artikel lesen | |
| 18.05. | OS Therapies GAAP EPS of -$0.27 | 1 | Seeking Alpha | ||
| 18.05. | OS Therapies: OS Therapies Reports First Quarter 2026 Financials and Provides Business Update | 688 | Newsfile | $5.5 million financing that closed on April 2, 2026 together with $5.7 million in capital raised in Q1-2026, expected to provide Company with cash runway into 2027$4.5 million of accrued VAT refunds... ► Artikel lesen | |
| 18.05. | OS Therapies Inc - 10-Q, Quarterly Report | 1 | SEC Filings | ||
| 15.05. | OS Therapies: OS Therapies to Announce First Quarter 2026 Financials on Monday, May 18, 2026 | 443 | Newsfile | New York, New York and Rockville, Maryland--(Newsfile Corp. - May 15, 2026) - OS Therapies, Inc. (NYSE American: OSTX) ("OS Therapies" or "the Company"), the world leader in gene-edited, listeria-based... ► Artikel lesen | |
| 14.05. | OS Therapies: OS Therapies Appoints Industry Leader Dr. Craig Eagle as Chief Medical Advisor | 528 | Newsfile | Appointment strengthens medical, regulatory, and commercial leadership as Company prepares to complete early market access regulatory filings in the U.S., U.K, Europe and Australia in anticipation... ► Artikel lesen | |
| 12.05. | Reportable, Inc.: Stonegate Capital Partners Updates Coverage on OS Therapies Inc. (OSTX) | 443 | Newsfile | Dallas, Texas--(Newsfile Corp. - May 12, 2026) - OS Therapies Inc. (NYSE American: OSTX): Stonegate Capital Partners updates their coverage on OS Therapies Inc. (NYSE American: OSTX). OS Therapies... ► Artikel lesen | |
| 30.04. | OS Therapies Inc - 8-K, Current Report | - | SEC Filings | ||
| 30.04. | EMA begins rolling review of OS Therapies' osteosarcoma treatment | 1 | Investing.com |
1 2 3 4 Weiter >>
64 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| NOVAVAX | 7,130 | -0,97 % | Handelsvolumen bei Novavax-Optionen erreicht Mehrmonatshoch | ||
| CRISPR THERAPEUTICS | 41,765 | -1,66 % | 3 Reasons to Buy CRISPR Therapeutics Stock | ||
| PALATIN TECHNOLOGIES | 9,000 | +6,19 % | Palatin Technologies, Inc.: Palatin to Begin Trading on Nasdaq Stock Exchange |
PRINCETON, N.J., May 18, 2026 /PRNewswire/ -- Palatin Technologies, Inc. (NYSE American: PTN), a biopharmaceutical company focused on the discovery and development... ► Artikel lesen | |
| OCUGEN | 1,186 | -1,33 % | Ocugen, Inc. Announces Binding Term Sheet with Roots Pharmaceutical to License OCU400 Modifier Gene Therapy for Retinitis Pigmentosa in the Middle East and North Africa | Cumulative sales milestones up to $255 million and modest upfront/near-term development milestonesRoyalties equaling 22% of net salesOcugen to manufacture and supply OCU400 MALVERN, Pa., July 13,... ► Artikel lesen | |
| NUREXONE BIOLOGIC | 0,294 | -9,54 % | NurExone-Tochter Exo-Top nimmt mexikanischen Exosomenmarkt ins Visier | ||
| PACIFIC BIOSCIENCES OF CALIFORNIA | 1,253 | -4,17 % | PacBio to Report Second Quarter 2026 Financial Results on August 5, 2026 | ||
| REDHILL BIOPHARMA | 0,705 | -3,56 % | RedHill Biopharma Ltd.: RedHill's Opaganib Receives FDA Rare Pediatric Disease Designation for Neuroblastoma in Addition to Current Orphan Drug Designation | The U.S. Food and Drug Administration (FDA) has granted rare pediatric disease designation to opaganib1 for the treatment of neuroblastoma, a type of cancer most... ► Artikel lesen | |
| IMMUNIC | 13,085 | -0,42 % | IMMUNIC, INC. - 8-K, Current Report | ||
| PHIO PHARMACEUTICALS | 1,040 | +4,01 % | Phio Pharmaceuticals Corp.: Phio Pharmaceuticals Announces Patent Milestone with Multiple Notices of Allowance and Grant Decision | King of Prussia, Pennsylvania--(Newsfile Corp. - July 15, 2026) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO) is a clinical-stage siRNA biopharmaceutical company developing therapeutics using its... ► Artikel lesen | |
| ONCO-INNOVATIONS | 0,385 | -1,28 % | Onco-Innovations Limited: Onco-Innovations Completes Analytical Reference Standard Preparation Program for ONC010's API | VANCOUVER, BC / ACCESS Newswire / July 10, 2026 / Onco-Innovations Limited (CBOE CA:ONCO)(OTCQB:ONNVF)(Frankfurt:W1H, WKN: A3EKSZ) ("Onco" or the "Company") announces the successful completion of its... ► Artikel lesen | |
| NOVOCURE | 13,385 | -6,72 % | JPMorgan nimmt NovoCure-Bewertung mit "Neutral" wieder auf | ||
| REVOLUTION MEDICINES | 163,45 | +4,37 % | Revolution Medicines: Nach Bauchspeicheldrüsenkrebs-Durchbruch - geht jetzt alles ganz schnell? | Eine Revolution im wahrsten Sinne des Unternehmensnamens: Die Biotech-Gesellschaft Revolution Medicines kann einen Paradigmenwechsel zur Behandlung von Bauchspeicheldrüsenkrebs einleiten. Die Datenlage... ► Artikel lesen | |
| OCULAR THERAPEUTIX | 8,050 | 0,00 % | Citizens reiterates Ocular Therapeutix stock rating on Dextenza sales | ||
| ROCKET PHARMACEUTICALS | 3,020 | +1,00 % | ROCKET PHARMACEUTICALS, INC. - S-8, Securities to be offered to employees in employee benefit plans | ||
| ARCTURUS THERAPEUTICS | 6,055 | 0,00 % | Arcturus Therapeutics (ARCT) Stock Jumps 5.7%: Will It Continue to Soar? |
OS THERAPIES INC gehört der Branche Biotechnologie an. Mit einer aktuellen Kursveränderung von +0,030 (+1,99 %) liegt der Kurs bei 1,540 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu OS THERAPIES INC finden Sie auf Wallstreet Online.